JCI - Citations to In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Citations to this article

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Published January 15, 1996
Citation Information: J Clin Invest. 1996;97(2):515-521. https://doi.org/10.1172/JCI118443.

View: Text | PDF

Research Article

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Text
PDF

Abstract

Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and IL-2 appears to produce dramatic regressions in patients with metastatic melanoma and renal cancer. However, the in vivo mechanism of TIL function is not known. We conducted an UCLA Human Subject Protection Committee, Recombinant DNA Advisory Committee, and FDA-approved clinical trial using genetically-marked TIL to test the hypothesis that these cells have unique, tumor-specific in vivo trafficking patterns. TIL and PBL (as a control effector cell population) were isolated and expanded in parallel in vitro in IL-2-containing medium for 4-6 wk. During the expansion, TIL and PBL were separately transduced with the amphotropic retroviral vectors LNL6 and G1Na. Transduced TIL and PBL were coinfused into patients and their respective numbers measured in tumor, peripheral blood, and normal tissues; integrated provirus could be quantitated and distinguished by DNA PCR. Nine patients were treated (six melanoma, three renal) and received between 4.5 x 10(8) and 1.24 x 10(10) total cells. Both "marked" TIL and PBL could be detected circulating in the peripheral blood, in some patients for up to 99 d after infusion. Marked TIL and/or PBL could be detected in tumor biopsies in six of nine patients as early as day 6 and as late as day 99 after infusion. No convincing pattern of preferential trafficking of TIL vs. PBL to tumor was noted. Moreover, concurrent biopsies of muscle, fat, and skin demonstrated the presence of TIL/PBL in comparable or greater numbers than in tumor in five patients. The results of this double gene marking trial provide interesting insights into the life span and trafficking of adoptively transferred lymphocytes, but do not support the hypothesis that TIL specifically traffic to tumor deposits.

Authors

J S Economou, A S Belldegrun, J Glaspy, E M Toloza, R Figlin, J Hobbs, N Meldon, R Kaboo, C L Tso, A Miller, R Lau, W McBride, R C Moen

Total citations by year

Year:	2022	2019	2018	2015	2013	2012	2011	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1997	1977	Total
Citations:	1	1	1	1	2	1	3	3	2	1	2	3	5	7	5	3	5	1	1	48

Citation information

Citations to this article (48)

Title and authors	Publication	Year
Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors? Li B	Frontiers in immunology	2022
Tumor characteristics associated with engraftment of patient‐derived non–small cell lung cancer xenografts in immunocompromised mice Y Chen, R Zhang, L Wang, AM Correa, A Pataer, Y Xu, X Zhang, C Ren, S Wu, QH Meng, J Fujimoto, VB Jensen, MB Antonoff, WL Hofstetter, RJ Mehran, G Pisimisis, DC Rice, B Sepesi, AA Vaporciyan, GL Walsh, SG Swisher, JA Roth, JV Heymach, B Fang	Cancer	2019
Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity VH Engelhard, AB Rodriguez, IS Mauldin, AN Woods, JD Peske, CL Slingluff	Journal of immunology (Baltimore, Md. : 1950)	2018
Advances in Cancer Research JD Peske, AB Woods, VH Engelhard	Advances in cancer research	2015
Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues CC Brinkman, JD Peske, VH Engelhard	Frontiers in immunology	2013
Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth C Shen, K Cheng, S Miao, W Wang, Y He, F Meng, J Zhang	Immunology Letters	2013
Adipose lineage specification of bone marrow-derived myeloid cells SM Majka, HL Miller, T Sullivan, PF Erickson, R Kong, M Weiser-Evans, R Nemenoff, R Moldovan, SA Morandi, JA Davis, DJ Klemm	Adipocyte	2012
Advances in Immunology E Pinaud, M Marquet, R Fiancette, S Péron, C Vincent-Fabert, Y Denizot, M Cogné	Advances in Immunology Volume 110	2011
Kidney Cancer PN Lara, E Jonasch	Kidney Cancer	2011
Targeted Therapeutics in Melanoma TF Gajewski, FS Hodi		2011
In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC) M Durai, C Krueger, Z Ye, L Cheng, A Mackensen, M Oelke, JP Schneck	Cancer Immunology, Immunotherapy	2008
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer BA Rabinovich, Y Ye, T Etto, JQ Chen, HI Levitsky, WW Overwijk, LJ Cooper, J Gelovani, P Hwu	Proceedings of the National Academy of Sciences	2008
Gene and Cell Therapy K Oka	Gene and Cell Therapy	2008
The Continuing Contribution of Gene Marking to Cell and Gene Therapy SK Tey, MK Brenner	Molecular Therapy	2007
Therapiekonzepte Onkologie S Seeber, HJ Schütte		2007
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells Q Zhang, TL Jang, X Yang, I Park, RE Meyer, S Kundu, M Pins, B Javonovic, T Kuzel, SJ Kim, LV Parijs, N Smith, L Wong, NM Greenberg, Y Guo, C Lee	The Prostate	2006
Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils FE Johansen, ES Baekkevold, HS Carlsen, IN Farstad, D Soler, P Brandtzaeg	Blood	2005
A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes N Schaft, J Dörrie, I Müller, V Beck, S Baumann, T Schunder, E Kämpgen, G Schuler	Cancer Immunology, Immunotherapy	2005
111Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo J Kelsen, J Agnholt, L Falborg, JT Nielsen, JL Rømer, HJ Hoffmann, JF Dahlerup	Clinical & Experimental Immunology	2004
T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? M Campoli, S Ferrone	Expert Review of Vaccines	2004
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy C Blank, TF Gajewski, A Mackensen	Cancer Immunology, Immunotherapy	2004
Tumor vaccines: from gene therapy to dendritic cells—the emerging frontier J Vieweg, J Dannull	Urologic Clinics of North America	2003
Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives E Biagi, C Bollard, R Rousseau, M Brenner	Journal of Biomedicine and Biotechnology	2003
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Second Edition, Revised and Expanded H Heslop, M Brenner, C Bollard	Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Second Edition, Revised and Expanded	2003
Immunotherapy of Cancer by Active Vaccination: Does Allogeneic Bone Marrow Transplantation after Non-Myeloablative Conditioning Provide a New Option? M Zöller	Technology in cancer research & treatment	2003
Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients N Meidenbauer, J Marienhagen, M Laumer, S Vogl, J Heymann, R Andreesen, A Mackensen	Journal of immunology (Baltimore, Md. : 1950)	2003
Recruitment of lymphocytes to the human liver PF Lalor, P Shields, AJ Grant, DH Adams	Immunology and Cell Biology	2002
Current status of adoptive immunotherapy of malignancies MA Morse, TM Clay, HK Lyerly	Expert Opinion on Biological Therapy	2002
Therapeutic options in the management of renal cell carcinoma JA Glaspy	Seminars in Oncology	2002
Gene Therapy of Cancer IV Lebedeva, CA Stein	Gene Therapy of Cancer	2002
Vacunas antitumorales en desarrollo clínico A Ribas, M Ribas-Mundó	Medicina Clínica	2002
Immunothérapie génique du cancer S Paul, R Étienne	Transfusion Clinique et Biologique	2002
Immunotherapy of urologic tumors EL Broghammer, TL Ratliff	Urologic Oncology: Seminars and Original Investigations	2002
Gene-Marking studies of hematopoietic cells CM Bollard, HE Heslop, MK Brenner	International Journal of Hematology	2001
Gene therapy for paediatric leukaemia HE Heslop, RF Rousseau, CM Bollard	Expert Opinion on Biological Therapy	2001
Specific Immunotherapy of Cancer in Elderly Patients S Matzku, M Z??ller	Drugs & Aging	2001
Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids K Kawai, H Hayashi, Y Ozaki, K Saijo, SQ Liu, H Akaza, T Ohno	Cytotechnology	2001
Specific Immunotherapy of Cancer in Elderly Patients: S Matzku, M Zller	Drugs & Aging	2001
Recent Developments in the Virus Therapy of Cancer TA Steele	Proceedings of the Society for Experimental Biology and Medicine	2000
Allogeneic Immunotherapy for Malignant Diseases J Gribben, J Schultze	Allogeneic Immunotherapy for Malignant Diseases	2000
In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients MH Shapero, SK Kundu, E Engleman, R Laus, WC van Schooten, TC Merigan	Cell Transplantation	2000
Thérapie génique en cancérologie : l'attente des résultats cliniques V Descamps, MT Duffour, H Haddada	Annales de l'Institut Pasteur/Actualités	1999
Multicenter, Randomized, Phase III Trial of CD8 + Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma RA Figlin, JA Thompson, RM Bukowski, NJ Vogelzang, AC Novick, P Lange, GD Steinberg, AS Belldegrun	Journal of Clinical Oncology	1999
Human melanoma therapy in the SCID mouse:In vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments B Cochlovius, A Perschl, GJ Adema, M Zller	International Journal of Cancer	1999
Blood Cell Biochemistry: Hematopoiesis and Gene Therapy LJ Fairbairn, NG Testa		1999
Spontaneous regression of a residual pineal tumor after resection of a cerebellar vermian germinoma T Fujimaki, K Mishima, A Asai, I Suzuki, T Kirino	Journal of Neuro-Oncology	1999
Can We Define the Mechanism of Antitumor Response Observed During Clinical Adoptive Immunotherapy? Y Merrouche, I Puisieux, M Favrot, S Negrier	JNCI Journal of the National Cancer Institute	1997
Nierentumoren G Staehler, S Pomer		1977

Citations to this article

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Abstract

Authors

Total citations by year

Citations to this article (48)

Sign up for email alerts